L. Mcnair

发表

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

V. Garg, Yijun Yang, Katia Alves, 2013, British journal of clinical pharmacology.

Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C

Tara L. Kieffer, H. Chu, S. Zeuzem, 2007, Hepatology.

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Trial of Merimepodib (VX-497) and Interferon-α in Previously Untreated Patients with Chronic Hepatitis C

E. Ette, M. Shiffman, T. Wright, 2005, Antiviral Therapy.

A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.

E. Ette, M. Shiffman, T. Wright, 2005, Antiviral therapy.

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Tara L. Kieffer, A. Kwong, M. Tausek, 2008 .

O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY

T. Asselah, X. Forns, G. Everson, 2014 .

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Jean-Michel Pawlotsky, Geoffrey Dusheiko, Tara L. Kieffer, 2009, The New England journal of medicine.

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

G. Everson, M. Sulkowski, J. McHutchison, 2009, The New England journal of medicine.

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study.

S. Zeuzem, P. Jansen, C. Weegink, 2006, Gastroenterology.

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

A. Kwong, I. Jacobson, Ira Jacobson, 2008, Current opinion in pharmacology.

Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study

A. Kablinger, F. Hefti, N. Goeders, 2012, Journal of psychopharmacology.

737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a

H. Chu, S. Zeuzem, P. Jansen, 2006 .

1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA

E. Lawitz, W. Symonds, M. Berrey, 2011 .

[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C

G. Everson, J. McHutchison, I. Jacobson, 2007 .

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

J. McHutchison, E. Lawitz, A. Muir, 2008, Journal of hepatology.

4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C

G. Everson, J. McHutchison, I. Jacobson, 2008 .

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders

William M. Lee, H. Bonkovsky, N. Afdhal, 2009, Hepatology.

Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.

P. Marcellin, F. Nevens, V. Garg, 2007, Journal of hepatology.

223 Prove1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Hepatitis C

G. Everson, J. McHutchison, I. Jacobson, 2008 .

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

E. Schiff, X. Forns, R. Chung, 2015, Gastroenterology.

Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a

M. Dijkgraaf, S. Zeuzem, P. Jansen, 2008, Scandinavian journal of gastroenterology.

DRAVET ENGAGE. Parent caregivers of children with Dravet syndrome: Perspectives, needs, and opportunities for clinical research

E. Wirrell, N. Huang, D. Bilder, 2021, Epilepsy & Behavior.

P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY

M. Manns, R. Fontana, X. Forns, 2014 .

1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS

E. Lawitz, W. Symonds, L. Fang, 2012 .

28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects

J. McHutchison, E. Lawitz, A. Muir, 2006 .

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Tara L. Kieffer, J. McHutchison, E. Lawitz, 2008, Journal of hepatology.

[592] NEOPTERIN AND ALT AS MARKERS OF INFLAMMATION IN CHRONIC HEPATITIS C PATIENTS DURING ADMINISTRATION OF THE HCV NS3-4A PROTEASE INHIBITOR TELAPREVIR (VX-950) IN COMBINATION WITH PEGINTERFERON ALFA 2a

S. Zeuzem, H. Reesink, H. Gelderblom, 2007 .

492 A phase II, placebo-controlled study of merimepodib (XV-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin

P. Marcellin, F. Nevens, Y. Horsmans, 2004 .